Indeed, there is little literature on pregnancy outcomes following the administration of PD-1 inhibitors, particularly in patients with Hodgkin’s lymphoma (HL) undergoing treatment with pembrolizumab. Here, PDCD1 is linked to Hodgkins lymphoma.